Active ingredients: canakinumab
What it is used for
CANAKINUMAB NOVARTIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 2 years or older including: Familial Cold Autoinflammatory Syndrome (FCAS)/Familial Cold Urticaria (FCU); Muckle-Wells Syndrome (MWS); Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA). CANAKINUMAB NOVARTIS is indicated for the treatment of active Systemic Juvenile Idiopathic Arthritis (sJIA) in patiens aged 2 years or older.
How to take it
The way to take this medicine is: Hard Surface Disinfectant.
- Store at 2 to 8 degrees Celsius
- Do not Freeze
- Protect from Light
- Shelf lifetime is 3 Years.
Always read the label. If symptoms persist see your healthcare professional.
Colourless to slightly brownish yellow solution, in a 2mL colourless glass vial with grey rubber stopper and green flip off cap.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient canakinumab
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems